Assembly Biosciences (NASDAQ:ASMB) Now Covered by Analysts at JMP Securities

JMP Securities assumed coverage on shares of Assembly Biosciences (NASDAQ:ASMB) in a research note published on Wednesday morning, Marketbeat Ratings reports. The firm issued a market outperform rating and a $38.00 price objective on the biopharmaceutical company’s stock.

ASMB has been the topic of several other research reports. Guggenheim increased their target price on Assembly Biosciences from $31.00 to $39.00 and gave the company a “buy” rating in a report on Monday, September 8th. HC Wainwright began coverage on Assembly Biosciences in a report on Monday, August 18th. They issued a “buy” rating and a $50.00 price objective on the stock. Citizens Jmp assumed coverage on Assembly Biosciences in a research report on Wednesday. They set a “mkt outperform” rating and a $38.00 target price on the stock. Finally, Zacks Research raised Assembly Biosciences to a “hold” rating in a report on Tuesday, August 19th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $41.25.

Assembly Biosciences Stock Performance

ASMB stock opened at $25.66 on Wednesday. The company’s 50 day moving average price is $22.51 and its 200 day moving average price is $16.52. The firm has a market capitalization of $196.81 million, a price-to-earnings ratio of -4.60 and a beta of 0.68. Assembly Biosciences has a fifty-two week low of $7.75 and a fifty-two week high of $27.17.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) EPS for the quarter, topping the consensus estimate of ($1.73) by $0.40. Assembly Biosciences had a negative net margin of 117.20% and a negative return on equity of 149.01%. The company had revenue of $9.63 million during the quarter, compared to analysts’ expectations of $5.30 million. Equities analysts forecast that Assembly Biosciences will post -6.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. acquired a new position in Assembly Biosciences during the first quarter worth approximately $113,000. Palumbo Wealth Management LLC grew its position in shares of Assembly Biosciences by 57.4% during the first quarter. Palumbo Wealth Management LLC now owns 17,986 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 6,559 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 6,823 shares during the period. Man Group plc purchased a new stake in Assembly Biosciences in the 4th quarter valued at $309,000. Finally, Geode Capital Management LLC raised its position in Assembly Biosciences by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock valued at $925,000 after purchasing an additional 3,312 shares during the last quarter. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.